Vu Sheryl-Phuc, Veit Kaleb, Sadikot Ruxana T
Division of Pulmonary, Critical Care & Sleep, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Int J Mol Sci. 2025 Feb 28;26(5):2184. doi: 10.3390/ijms26052184.
Chronic obstructive pulmonary disease (COPD) is a clinical syndrome that presents as airflow limitation with poor reversibility accompanied by dynamic hyperinflation of the lung. It is a complex disease with chronic inflammatory airway changes caused by exposure to noxious particles or gases, such as cigarette smoke. The disease involves persistent inflammation and oxidative stress, perpetuated by frequent exacerbations. The prevalence of COPD is on the rise, with the prediction that it will be the leading cause of morbidity and mortality over the next decade. Despite the global burden of COPD and its associated morbidity and mortality, treatment remains limited. Although the understanding of the pathogenesis of COPD has increased over the last two decades, molecular approaches to develop new therapies for the treatment of COPD have lagged. Here, we review the molecular approaches that have the potential for developing novel therapies for COPD.
慢性阻塞性肺疾病（COPD）是一种临床综合征，表现为气流受限且可逆性差，并伴有肺动态过度充气。它是一种复杂的疾病，由接触有害颗粒或气体（如香烟烟雾）引起慢性炎症性气道改变。该疾病涉及持续的炎症和氧化应激，并因频繁发作而持续存在。COPD的患病率正在上升，预计在未来十年它将成为发病和死亡的主要原因。尽管COPD在全球范围内造成负担及其相关的发病率和死亡率，但治疗方法仍然有限。尽管在过去二十年中对COPD发病机制的认识有所增加，但开发治疗COPD新疗法的分子方法却滞后了。在此，我们综述了具有开发COPD新疗法潜力的分子方法。
